WuXi Biologics has reinforced their position as a leader in the contract services marketplace, and continues to reinvest in their capabilities, providing the biopharmaceutical market with an expanded service portfolio.
New York, NY (PRWEB) February 02, 2016
BioProcess International (BPI), a business-to-business publication dedicated to delivering cutting-edge information focused on the development and manufacture of biopharmaceuticals and therapeutics, announces an agreement with WuXi Biologics to become a premier sponsor of the 2016 BioProcess International Awards – Recognizing Excellence in the People, Organizations and Technology Applications in Bioprocessing.
The BPI Awards has been developed to encourage the leaders, scientists, manufacturers, and suppliers to raise the awareness of their individual achievements, collaborations, successful business strategies, social corporate responsibility and technology applications that will allow the industry to deliver better, more effective treatments to a global patient base.
“The 2016 BPI Award program honors the innovative companies and individuals that are driving the biopharmaceutical industry forward,” said Brian Caine, BioProcess International’s Co-Founder and Publisher. “WuXi Biologics has reinforced their position as a leader in the contract services marketplace, and continues to reinvest in their capabilities, providing the biopharmaceutical market with an expanded service portfolio. We welcome them as a premier sponsor of the 2016 BioProcess International Awards.”
“In order to provide more effective and affordable medicines to our global community, it is imperative as an industry we continue to find novel means to enhance the efficiency, safety and economics of bioprocessing,” said Chris Chen, PhD, Chief Executive Officer of WuXi Biologics (a wholly-owned subsidiary of WuXi AppTec). “WuXi Biologics is proud to sponsor those individuals and companies that bring new insights and mechanisms to improve all aspects of biologics manufacturing,”
The nominations deadline is June 30, 2016. To submit your nomination visit: http://www.bioprocessintl.com/awards.
Awards will be granted recognizing achievements within the following categories:
- Best Collaboration
- Excellence in Leadership
- Excellence in Facility Design or Retrofit
- Emerging Company
- Corporate Citizenship
- Best Technology Application - Upstream (user or supplier)
- Best Technology Application - Downstream (user or supplier)
- Best Technology Application - Analytical (user or supplier)
WuXi Biologics (a wholly-owned subsidiary of WuXi AppTec) is a leading open-access technology platform contract services company. As a premier Contract Discovery, Development and Manufacturing Organization (CDMO), WuXi Biologics provides our worldwide clients with the necessary expertise, quality and capacities to develop biologic drugs from concept to commercialization. Along with our WuXi AppTec affiliates, we provide the world with the ONE true single-source approach that saves our clients critical time and money. Our company history and achievements demonstrate our commitment to providing a truly ONE-stop service offering and value proposition to our global clients. Services provided include five therapeutic antibody discovery platforms, cell line engineering, cell culture, purification, formulation and assay development, and bulk drug substance and drug product GMP manufacturing. More information: http://www.wuxibiologics.com
About BioProcess International
BioProcess International is part of the T&F Informa Knowledge and Networking Group, the leading provider of scientific, technological, and business information to the global life science community.
To submit a nomination or request sponsorship information, please visit: http://www.bioprocessintl.com/awards